Caldera raises $278M in reverse merger with Synlogic
What's the deal? Caldera TherapeuticsDealroom has a profile for this one. Try Dealroom →, a clinical-stage biotech developing an inflammatory bowel disease treatment, has agreed to merge with publicly traded SynlogicDealroom has a profile for this one. Try Dealroom → in an all-stock deal, alongside a concurrent $278 million private placement.
Both companies will become subsidiaries of a new holding company. The combined entity will operate as Caldera Therapeutics and intends to trade on the Nasdaq Capital Market under the ticker "CALD."
What's the endgame? Caldera is building CLD-423, described as a potential first-in-class TL1A x IL-23p19 bispecific antibody for IBD and other immune-mediated diseases. The financing is set to fund Phase 2 trials in ulcerative colitis and Crohn's disease.
Who's backing it? The upsized private placement drew a syndicate of healthcare institutional investors and mutual funds, including Bain Capital Life SciencesDealroom has a profile for this one. Try Dealroom →, TCGXDealroom has a profile for this one. Try Dealroom →, Atlas Venture, venBio PartnersDealroom has a profile for this one. Try Dealroom →, Omega FundsDealroom has a profile for this one. Try Dealroom →, Blackstone, LAVDealroom has a profile for this one. Try Dealroom →, Wellington Management, Janus Henderson Investors, Sirenia Capital Management, and Vivo Capital.
Why the structure? The reverse merger gives Caldera a public listing without a traditional IPO — and effectively amounts to Caldera taking over Synlogic. On closing, pre-merger Caldera stockholders are expected to own roughly 62.8% of the combined company, private-placement investors about 34.9%, and pre-merger Synlogic stockholders just 2.3%. Combined cash at closing, plus the private placement proceeds, is expected to fund operations into 2029.
The transaction and the concurrent financing are expected to close by early 2027, subject to customary closing conditions.
The signal: The deal reflects continued biotech interest in TL1A-targeting therapies for IBD, a mechanism that has attracted large-scale investment across the sector. By pairing a reverse merger with a nine-figure raise, Caldera secures both a public listing and a multi-year runway in a single move.
Read more: Synlogic
